PARP inhibitors in cancer therapy: an update

Bibliography

• Hottiger MO, Hassa PO, Luscher B, Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010;35:208-19
   PubMed Web of Science ®Google Scholar
• Ferraris DV. Evolution of Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 2010;53:4561-84
   PubMed Web of Science ®Google Scholar
• Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28
   PubMed Web of Science ®Google Scholar
• Yelamos J, Farres J, Llacuna L, PARP-1 and PARP-2: new players in tumour development. Am J Cancer Res 2011;1:328-46
   PubMed Web of Science ®Google Scholar
• Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 2009;47:13-26
   PubMed Web of Science ®Google Scholar
• Hochegger H, Dejsuphong D, Fukushima T, Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 2006;25:1305-14
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Horvath B, Kechrid M, Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radical Biol Med 2011;51:1774-88
   PubMed Web of Science ®Google Scholar
• Kauppinen TM, Swanson RA. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 2007;145:1267-72
   PubMed Web of Science ®Google Scholar
• Moroni F, Cozzi A, Chiarugi A, Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase. Br J Pharmacol 2012;165:1487-500
   PubMed Web of Science ®Google Scholar
• de Murcia JM, Ricoul M, Tartier L, Functional interactions between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-63
   PubMedGoogle Scholar
• Dantzer F, Mark M, Quenet D, Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and spermiogenesis. Proc Natl Acad Sci USA 2006;103:14854-9
   PubMed Web of Science ®Google Scholar
• Bai P, Houten SM, Huber A, Peroxisome proliferator-activated receptor (PPAR)-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor/PPARgamma heterodimer. J Biol Chem 2007;282:37738-46
   PubMed Web of Science ®Google Scholar
• Yelamos J, Monreal Y, Saenz L, PARP-2 deficiency affects the survival of CD4+ CD8+ double-positive thymocytes. EMBO J 2006;25:4350-60
   PubMed Web of Science ®Google Scholar
• Rippman JF, Damm K, Schnapp A. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length. J Mol Biol 2002;323:217-24
   Google Scholar
• Rouleau M, Patel A, Hendzel MJ, PARP inhibition: PARP 1 and beyond. Nat Rev Cancer 2010;10:293-301
   PubMed Web of Science ®Google Scholar
• Huang SM, Mishina YM, Liu S, Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature 2009;461:614-20
   PubMed Web of Science ®Google Scholar
• Kleine H, Poreba E, Lesniewicz K, Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell 2008;32:57-69
   PubMed Web of Science ®Google Scholar
• Loseva O, Jemth AS, Bryant HE, PARP-3 Is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. J Biol Chem 2010;285:8054-60
   PubMed Web of Science ®Google Scholar
• Boehler C, Gauthier LR, Mortusewicz O, Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci USA 2011;108:2783-8
   PubMed Web of Science ®Google Scholar
• Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssay 2004;8:882-93
   Google Scholar
• Wahlberg E, Karlberg T, Kouznetsova E, Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30:283-8
   PubMed Web of Science ®Google Scholar
• Karlberg T, Hammarstrom M, Schutz P, Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 2010;49:1056-8
   Google Scholar
• Papeo G, Forte B, Orsini P, Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Patents 2009;19(10):1377-400
   PubMed Web of Science ®Google Scholar
• Lehtio L, Jemth AS, Collins R, Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem 2009;52:3108-11
   PubMed Web of Science ®Google Scholar
• Lehtio L, Collins R, van den Berg S, Zinc binding catalytic domain of human tankyrase 1. J Mol Biol 2008;379:136-45
   PubMed Web of Science ®Google Scholar
• Karlberg T, Markova N, Johansson I, Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J Med Chem 2010;53:5352-5
   PubMed Web of Science ®Google Scholar
• Narwal M, Venkannagari H, Lehtio L. Structural basis of selective inhibition of human tankyrases. J Med Chem 2012;55:1360-7
   PubMed Web of Science ®Google Scholar
• Kirby CA, Cheung A, Fazal A, Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallogr Sect F 2012;F68:115-18
   Google Scholar
• Gunaydin H, Gu Y, Huang X. Novel binding mode of a potent and selective tankyrase inhibitor. PLoS One 2012;7:e33740
   Google Scholar
• Shultz MD, Kirby CA, Stams T, [1,2,4]Triazol-3-ylsulfanylmethyl)-3-phenyl- [1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem 2012;55:1127-36
   Google Scholar
• Liu X, Shi Y, Maag DX, Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012;18:510-23
   PubMed Web of Science ®Google Scholar
• Patel A, De Lorenzo SB, Flatten KS, Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 2012;18:1655-62
   PubMed Web of Science ®Google Scholar
• Curtin NJ. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. Drug Discov Today 2012;9:e51-8
   Google Scholar
• Farmer H, McCabe N, Lord CJ, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82
   PubMed Web of Science ®Google Scholar
• Anders CK, Winer EP, Ford JM, Poly(ADP-ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res 2010;16:4702-10
   PubMed Web of Science ®Google Scholar
• Hunt CR, Gupta A, Horikoshi N, Does pTEN loss impair DNA double-strand break repair by homologous recombination? Clin Cancer Res 2012;18:920-2
   Google Scholar
• Ming M, He YY. PTEN in DNA damage repair. Cancer Lett 2012;319:125-9
   PubMed Web of Science ®Google Scholar
• Mendes-Pereira AM, Martin SA, Brough R, Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22
   PubMed Web of Science ®Google Scholar
• Garcia-Cao I, Song MS, Hobbs RM, Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012;149:49-62
   PubMed Web of Science ®Google Scholar
• Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-14
   PubMed Web of Science ®Google Scholar
• Forster MD, Dedes KJ, Sandhu S, Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011;8:302-6
   PubMed Web of Science ®Google Scholar
• Giannini G, Ristori E, Cerignoli F, Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-54
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010;7:153-62
   PubMed Web of Science ®Google Scholar
• Vilar E, Bartnik CM, Stenzel SL, Mre11 deficiency increases sensitivity to poly (ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011;71:2632-42
   PubMedGoogle Scholar
• Williamson CT, Muzik H, Turhan AG, ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010;9:347-57
   PubMed Web of Science ®Google Scholar
• Brenner JC, Feng FY, Han S, PARP-1 Inhibition as a target strategy to treat Ewing's sarcoma. Cancer Res 2012;72:1608-13
   PubMed Web of Science ®Google Scholar
• Leonetti C, Biroccio A, Graziani G, Tentori L. Targeted therapy for brain tumours: role of PARP inhibitors. Curr Cancer Drug Targets 2012;12:218-36
   PubMed Web of Science ®Google Scholar
• Pyriochou A, Olah G, Deitch EA, Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med 2008;22:113-18
   PubMed Web of Science ®Google Scholar
• Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012;19:3907-21
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer. Cancer Discov 2012;2:1048-63
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, Garcia-Garcia C, Serra V, PI3K Inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition. Cancer Discov 2012;2:1036-47
   PubMed Web of Science ®Google Scholar
• Bajrami I, Kigozi A, Van Weverwijk A, Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol Med 2012;4:1-10
   Google Scholar
• Megnin-Chanet F, Bollet MA, Hall J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci 2010;67:3649-62
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. US20120046303; 2012
   Google Scholar
• Javle M, Curtin NJ. The potential for poly(ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011;3:257-67
   PubMedGoogle Scholar
• Palma JP, Wang YC, Rodriguez LE, ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009;15:7277-90
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. WO201083220; 2010
   Google Scholar
• Abbott Laboratories. WO201083199; 2010
   Google Scholar
• Nerviano Medical Sciences S.r.l. WO201106803; 2011
   Google Scholar
• Nerviano Medical Sciences S.r.l. WO201106794; 2011
   Google Scholar
• Nerviano Medical Sciences S.r.l. WO2012016876; 2012
   Google Scholar
• Zhejiang Beta Pharma, Inc. WO201206958; 2012
   Google Scholar
• AstraZeneca AB; Abbott GmbH & Co KG. WO201041051; 2010
   Google Scholar
• Menear KA, Adcock C, Boulter R, 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91
   PubMed Web of Science ®Google Scholar
• AZ updates on olaparib and TC5214 20 December 2011
   Google Scholar
• AstraZeneca AB. WO201107145; 2011
   Google Scholar
• Angion Biomedica Corp. US20110098304; 2011
   Google Scholar
• Cadila Healthcare Ltd. WO201214221; 2012
   Google Scholar
• Nerviano Medical Sciences S.r.l. WO2010133647; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO201085570; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2010111626; 2010
   Google Scholar
• Biomarin Pharmaceutical, Inc. WO2011130661; 2011
   Google Scholar
• Biomarin Pharmaceutical, Inc. WO201197334; 2011
   Google Scholar
• Biomarin Pharmaceutical, Inc. WO201197602; 2011
   Google Scholar
• Thomas HD, Calabrese CR, Batey MA, Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56
   PubMed Web of Science ®Google Scholar
• Drew Y, Ledermann JA, Jones A, Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J Clin Oncol 2011;29(Suppl):abstract 3104
   Google Scholar
• Pfizer, Inc. WO201198971; 2011
   Google Scholar
• Eisai, Inc. US20110092478; 2011
   Google Scholar
• Phase 2 study of the Poly(ADP-ribose) polymerase inhibitor E7016 in combination with temozolomide in subjects with wild type BRAF stage IV or unresectable stage III melanoma. Protocol IDs E7016-A001-201. NCT01605162
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. WO2011014681; 2011
   Google Scholar
• Ledford H. Drug candidates derailed in case of mistaken identity. Nature 2012;483:519
   Google Scholar
• Chiarugi A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci 2012;33:42-8
   PubMed Web of Science ®Google Scholar
• Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 2011;29:373-4
   PubMed Web of Science ®Google Scholar
• Tulin A. Re-evaluating PARP1 inhibitor in cancer. Nat Biotechnol 2011;29:1078-9
   Google Scholar
• Oplustilova L, Wolanin K, Mistrik M, Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012;11:3837-50
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 2012;7:e46614
   PubMed Web of Science ®Google Scholar
• Jones P. Profiling PARP inhibitors. Nat Biotechnol 2012;30:249-50
   Google Scholar
• Title of the 1959 song composed by Cy Coleman, with lyrics by Carolyn Leigh and interpreted, among others, by Frank Sinatra
   Google Scholar